Cargando…
Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells
Chemoresistance renders current chemotherapy regimens ineffective against advanced epithelial ovarian cancer (EOC). Carboplatin (the first-line chemotherapeutic agent to treat EOC) induces cell death by regulating multiple signaling pathways. The objective of this study is to identify the signaling...
Autores principales: | Han, Xiaolu, Chen, Huachen, Zhou, Jiesi, Steed, Helen, Postovit, Lynne-Marie, Fu, YangXin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121386/ https://www.ncbi.nlm.nih.gov/pubmed/30049957 http://dx.doi.org/10.3390/ijms19082184 |
Ejemplares similares
-
The p38 MAPK inhibitor SB203580 differentially modulates LPS-induced interleukin 6 expression in macrophages
por: Shi, Qinghai, et al.
Publicado: (2015) -
In vitro modeling of COPD inflammation and limitation of p38 inhibitor – SB203580
por: Meng, Aihong, et al.
Publicado: (2016) -
SB203580—A Potent p38 MAPK Inhibitor Reduces the Profibrotic Bronchial Fibroblasts Transition Associated with Asthma
por: Paw, Milena, et al.
Publicado: (2021) -
The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4(+)Foxp3(+) Regulatory T Cells
por: He, Tianzhen, et al.
Publicado: (2018) -
SB203580 Modulates p38 MAPK Signaling and Dengue Virus-Induced Liver Injury by Reducing MAPKAPK2, HSP27, and ATF2 Phosphorylation
por: Sreekanth, Gopinathan Pillai, et al.
Publicado: (2016)